| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome
|
Rodés-Cabau, Josep
|
|
2009
|
104 |
6 |
p. 750-757
8 p.
|
artikel
|
| 2 |
Association of a Unique Cardiovascular Risk Profile With Outcomes in Hispanic Patients Referred for Percutaneous Coronary Intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry)
|
Parikh, Shailja V.
|
|
2009
|
104 |
6 |
p. 775-779
5 p.
|
artikel
|
| 3 |
Cardiovascular Risk Factors and Coronary Atherosclerosis in Retired National Football League Players
|
Chang, Alice Y.
|
|
2009
|
104 |
6 |
p. 805-811
7 p.
|
artikel
|
| 4 |
Cholesteryl Ester Transfer Protein, Coronary Calcium, and Intima-Media Thickness of the Carotid Artery in Middle-Age Japanese Men
|
Okamura, Tomonori
|
|
2009
|
104 |
6 |
p. 818-822
5 p.
|
artikel
|
| 5 |
Comparison of Blood Glucose Values on Admission for Acute Myocardial Infarction in Patients With Versus Without Diabetes Mellitus
|
Ishihara, Masaharu
|
|
2009
|
104 |
6 |
p. 769-774
6 p.
|
artikel
|
| 6 |
Comparison of Long Versus Short (“Spot”) Drug-Eluting Stenting for Long Coronary Stenoses
|
Katritsis, Demosthenes G.
|
|
2009
|
104 |
6 |
p. 786-790
5 p.
|
artikel
|
| 7 |
Contents
|
|
|
2009
|
104 |
6 |
p. A8-A9
nvt p.
|
artikel
|
| 8 |
Editorial Board
|
|
|
2009
|
104 |
6 |
p. A6-
1 p.
|
artikel
|
| 9 |
Effect of Balloon Valvuloplasty in Patients With Severe Aortic Stenosis on Levels of N-Terminal Pro-B-Type Natriuretic Peptide
|
Spargias, Konstantinos
|
|
2009
|
104 |
6 |
p. 846-849
4 p.
|
artikel
|
| 10 |
Effect of Blood Hematocrit and Erythrocyte Deformability on Adenosine 5′-Diphosphate Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy
|
Cecchi, Emanuele
|
|
2009
|
104 |
6 |
p. 764-768
5 p.
|
artikel
|
| 11 |
Effect of Habitual Aerobic Exercise on Body Weight and Arterial Function in Overweight and Obese Men
|
Miyaki, Asako
|
|
2009
|
104 |
6 |
p. 823-828
6 p.
|
artikel
|
| 12 |
Effect of Transcatheter Pulmonary Valve Implantation on Short-Term Right Ventricular Function as Determined by Two-Dimensional Speckle Tracking Strain and Strain Rate Imaging
|
Moiduddin, Nasser
|
|
2009
|
104 |
6 |
p. 862-867
6 p.
|
artikel
|
| 13 |
Effects of Increasing High-Density Lipoprotein Cholesterol and Decreasing Low-Density Lipoprotein Cholesterol on the Incidence of First Acute Coronary Events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study)
|
Cui, Yadong
|
|
2009
|
104 |
6 |
p. 829-834
6 p.
|
artikel
|
| 14 |
Effects of Percutaneous Aortic Valve Replacement on Coronary Blood Flow Assessed With Transesophageal Doppler Echocardiography in Patients With Severe Aortic Stenosis
|
Ben-Dor, Itsik
|
|
2009
|
104 |
6 |
p. 850-855
6 p.
|
artikel
|
| 15 |
Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis † † Conflicts of interest: Dr. White reports receiving research support during the past 12 months from the National Institutes of Health, Bethesda, Maryland; the Catherine and Patrick Donaghue Medical Research Foundation, West Hartford, Connecticut; the American Heart Association, Dallas, Texas; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Dr. White presently serves as a safety consultant to Gilead Sciences, Inc., Foster City, California; Myriad Genetics, Inc., Salt Lake City, Utah; NicOx S.A., Sophia-Antipolis, France; Takeda Research and Development Group, Deerfield, Illinois; and Teva Neuroscience, Inc., Kansas City, Missouri. Dr. Schnitzer reports receiving research support from the National Institutes of Health; Pfizer Laboratories, Inc., New York, New York; Wyeth Laboratories, Madison, New Jersey; Nordic Bioscience, Herlev, Denmark; Novartis Pharmaceuticals Corporation; Genzyme Corporation, Cambridge, Massachusetts; and Pozen, Inc., Chapel Hill, North Carolina. Dr. Schnitzer presently serves as a consultant to Logical Therapeutics, Inc., Waltham, Massachusetts; NicOx, Inc., Warren, New Jersey; Merck & Company, Inc., Whitehouse Station, New Jersey; SantoSolve AS, Oslo, Norway; Solstice Neurosciences, South San Francisco, California; and Horizon Therapeutics, Northbrook, Illinois. Dr. Schnitzer is a noninvested shareholder of NicOx S.A. Mrs. Fleming is an employee of NicOx, Inc. Drs. Duquesroix and Beekman are employees of NicOx, S.A.
|
White, William B.
|
|
2009
|
104 |
6 |
p. 840-845
6 p.
|
artikel
|
| 16 |
Ethnic-Specific Risks for Atherosclerotic Calcification of the Thoracic and Abdominal Aorta (from the Multi-Ethnic Study of Atherosclerosis)
|
Allison, Matthew A.
|
|
2009
|
104 |
6 |
p. 812-817
6 p.
|
artikel
|
| 17 |
Impact of Homocysteine-Lowering Vitamin Therapy on Long-Term Outcome of Patients With Coronary Artery Disease
|
Mager, Aviv
|
|
2009
|
104 |
6 |
p. 745-749
5 p.
|
artikel
|
| 18 |
Persistent Tricuspid Regurgitation and Its Predictor in Adults After Percutaneous and Isolated Surgical Closure of Secundum Atrial Septal Defect
|
Toyono, Manatomo
|
|
2009
|
104 |
6 |
p. 856-861
6 p.
|
artikel
|
| 19 |
Prognostic Impact of Q Waves on Presentation and ST Resolution in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
|
Kumar, Saurabh
|
|
2009
|
104 |
6 |
p. 780-785
6 p.
|
artikel
|
| 20 |
Relation Between Framingham Risk Categories and the Presence of Functionally Relevant Coronary Lesions as Determined on Multislice Computed Tomography and Stress Testing
|
Nucifora, Gaetano
|
|
2009
|
104 |
6 |
p. 758-763
6 p.
|
artikel
|
| 21 |
Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus
|
Braga, Manoela F.B.
|
|
2009
|
104 |
6 |
p. 835-839
5 p.
|
artikel
|
| 22 |
The Editor's Roundtable: Intracoronary Hyperoxemic Therapy in Acute Myocardial Infarction
|
Friedewald, Vincent E.
|
|
2009
|
104 |
6 |
p. 791-797
7 p.
|
artikel
|
| 23 |
Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension † † Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.
|
Hampole, Chetan V.
|
|
2009
|
104 |
6 |
p. 868-872
5 p.
|
artikel
|
| 24 |
Usefulness of Statin–Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease
|
Teoh, Hwee
|
|
2009
|
104 |
6 |
p. 798-804.e2
79603 p.
|
artikel
|
Tijdschrift beschrijving